Introduction  ||| S:0 E:13 ||| NN
to  ||| S:13 E:16 ||| TO
a  ||| S:16 E:18 ||| DT
special  ||| S:18 E:26 ||| JJ
supplement ||| S:26 E:36 ||| NN
:  ||| S:36 E:38 ||| :
Evidence  ||| S:38 E:47 ||| NN
for  ||| S:47 E:51 ||| IN
the  ||| S:51 E:55 ||| DT
implementation ||| S:55 E:69 ||| NN
,  ||| S:69 E:71 ||| ,
effects ||| S:71 E:78 ||| NNS
,  ||| S:78 E:80 ||| ,
and  ||| S:80 E:84 ||| CC
impact  ||| S:84 E:91 ||| NN
of  ||| S:91 E:94 ||| IN
the  ||| S:94 E:98 ||| DT
integrated  ||| S:98 E:109 ||| JJ
community  ||| S:109 E:119 ||| NN
case  ||| S:119 E:124 ||| NN
management  ||| S:124 E:135 ||| NN
strategy  ||| S:135 E:144 ||| NN
to  ||| S:144 E:147 ||| TO
treat  ||| S:147 E:153 ||| VB
childhood  ||| S:153 E:163 ||| FW
infection  ||| S:163 E:174 ||| FW
